The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EBMT-EHA CAR-T 2019 | Improving treatment outcomes of CAR T-cell therapy
In this video, Stanley Riddell, MD, of Fred Hutchinson Cancer Research Center, Seattle, WA., discusses improving treatment outcomes with CAR T-cell therapy by identifying different targets such as CD22. Dr Riddell goes on to explain the latest research at Fred Hutchinson Cancer Research Center that looks at improving CAR design to improve outcomes. Recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and European Hematology Association (EHA).
